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Abstract
© 2017 Svetlana F. Khaiboullina et al. Limb-girdle muscular dystrophy type 2 (LGMD2B) is a
mild form of dysferlinopathy, characterized by limb weakness and wasting. It is an autosomal
recessive  disease,  with  currently  140  mutations  in  the  LGMD2B  gene  identified.  Lack  of
functional  dysferlin  inhibits  muscle  fiber  regeneration  in  voluntary  muscles,  the  main
pathological finding in LGMD2B patients. However, the immune system has been suggested to
contribute to muscle cell death and tissue regeneration. Serum levels of 27 cytokines wer e
evaluated in a dysferlinopathy patient. Levels of 8 cytokines differed in patient serum compared
to controls. Five cytokines (IL-10, IL-17, CCL2, CXCL10, and G-CSF) were higher while 3 were
lower in the patient than in controls (IL-2, IL-8, and CCL11). Together, these data on serum
cytokine profile of this dysferlinopathy patient suggest immune response activation, which could
explain leukocyte infiltration in the muscle tissue.
http://dx.doi.org/10.1155/2017/3615354
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